Nanoscope Therapeutics Announces Presentations at the Optogenetics and Optical Manipulation Conference

Nanoscope Therapeutics Announces Presentations at the Optogenetics and Optical Manipulation Conference

DALLASJan. 23, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced an oral presentation and a poster presentation at the Optogenetics and Optical Manipulation Conference as part of the SPIE Photonics West BiOS Program, taking place January 28-February 2, 2023 in San Francisco.

Details for the oral presentation are as follows:

Abstract Title: Functionalizing inner retina with multi-characteristic opsin arrested further degeneration and functional deterioration
Abstract Number: 12366-10
Session Name: 3. Clinical Applications
Session Date: Sunday, January 29, 2023
Presentation Time11:40 a.m.-12:00 p.m. PT
Location: Moscone Center, Room 101 (Level 1 South Lobby)
Presenter: Dr. Samarendra Mohanty, President and Chief Scientific Officer of Nanoscope Therapeutics

In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will discuss the results of intravitreally delivered AAV-carried MCO-010 in multiple mice models of retinal degeneration, including retinitis pigmentosa and Stargardt disease, that showed arrest of further retinal degeneration as evaluated by optical coherence tomography (OCT), electroretinogram (ERG) and immuno-histochemistry (IHC).

Details for the poster presentation are as follows:

Abstract Title: OCT-guided variable spot electrophysiology platform for correlated structural and functional assessment of optogenetic intervention
Abstract Number: 12366-24
Session Name: BiOS poster session
Session Date: Sunday, January 29, 2023
Presentation Time5:30-7:00 p.m. PT
Location: Moscone Center, Level 2 West

Dr. Mohanty will detail the development of image-guided spatially resolved functional assessment of retina using OCT-guided variable-spot stimulated electroretinogram (vsERG). The OCT-vsERG platform is currently used to monitor diseased areas in retina of patients with Stargardt macular degeneration and to measure functional changes after optogenetic therapy.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.